Mutant biologics: The 2010 health-reform legislation's potential impact on reducing biologic research and development costs

Georgetown Law Journal

Volumn 100, Issue 6, 2012, Pages 2291-2324

  Polovina, Julie D ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867279537     PISSN: 00168092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Alfred B. Engelberg et al., Balancing Innovation, Access, and Profits-Market Exclusivity for Biologics, 361 NEW ENG. J. MED. 1917, 1918 (2009).
2. Krista Hessler Carver et al., An Unofficial Legislative History of the Biologics Price Competition and Innovation Act of 2009, 65 FOOD&DRUG L.J. 671, 807 (2010).
3. CONG. BUDGET OFFICE, PUB. NO. 2589, RESEARCH AND DEVELOPMENT IN THE PHARMACEUTICAL INDUSTRY 3-4 (2006).
4. Ingrid Kaldre, The Future of Generic Biologics: Should the United States "Follow-on" the European Pathway?, 2008 DUKE L. & TECH. REV. 0009
5. WENDY H. SCHACHT & JOHN R. THOMAS, CONG. RESEARCH SERV., RL 33901, FOLLOW-ON BIOLOGICS: INTELLECTUAL PROPERTY AND INNOVATION ISSUES 21-24 (2010);
6. Joyce Wing Yan Tam, Biologics Revolution: The Intersection of Biotechnology, Patent Law, and Pharmaceutical Regulation, 98 GEO. L.J. 535, 538-39 (2010).
7. Jacqueline Wright Bonilla, Biosimilars-The View from the US, SCIENCE|BUSINESS (Apr. 6, 2011), http://www.sciencebusiness.net/news/74945/ Biosimilars-%E2%80%93-the-view-from-the-US
8. Joseph A. DiMasi et al., The Price of Innovation: New Estimates of Drug Development Costs, 22 J. HEALTH ECON. 151, 181 (2003);
9. Andrew Jack, Big Drug Groups Urged To Buy inTest Products, FIN. TIMES (Jan. 31, 2010, 10:46 PM), http://www.ft.com/intl/cms/s/0/2ed73272-0eb6- 11dfbd79- 00144feabdc0.html#axzz1p2bzSM8N
10. Gregory N. Mandel, The Generic Biologics Debate: Industry's Unintended Admission That Biotech Patents Fail Enablement, 11 VA. J. L. & TECH. 8, 21, at 7 (2006).
11. Timothy Jost, Implementing Health Reform: Pre-Existing Condition Coverage, HEALTH AFF. BLOG (July 30, 2010, 3:07 PM), http://healthaffairs.org/ blog/2010/07/30/implementing-health-reform-preexisting- condition-coverage/.
12. JAMES N. CZABAN ET AL., BUREAU OF NAT'L AFFAIRS, PANACEA OR POISON PILL? MAKING SENSE OF THE NEW BIOSIMILARS LAW 1 (2010) (stating that biologics are "the fastest growing and arguably most important segment of the health care industry").
13. Richard G. Frank, Regulation of Follow-on Biologics, 357 NEW ENG. J. MED. 841, 842 (2007).
14. Richard F. Kingham & Grant H. Castle, Data and Marketing Exclusivity for Pharmaceuticals in the European Community, 55 FOOD&DRUG L.J. 209, 209 (2000).
15. Henry A. Waxman, Chairman, House Comm. on Energy & Commerce (June 24, 2009), available at http://democrats.energy commerce.house.gov/Press-111/ 20090625/biologicsresponse.pdf
16. Catherine Larkin, FDA's Rules for Copying Amgen, Roche Drugs Coming 'Very Soon', BLOOMBERG (Feb. 18, 2011), http://www.bloomberg. com/news/2011-02-18/ fda-says-rules-for-copying-amgen-biotechnology-drugs-to-arrive-very-soon-. html.
17. Mark J. Jakiela, Contribution Attribution As the Possible Next Step for "Crowdsourced" Engineering Design and Product Development, 30 WASH. U. J.L. & POL'Y 79, 80 (2009). 138.
18. Timothy K. Armstrong, Shrinking the Commons: Termination of Copyright Licenses and Transfers for the Benefit of the Public, 47 HARV. J. ON LEGIS. 359, 361 (2010).
19. ANDROID OPEN SOURCE PROJECT, http://source.android.com/index.html (last visited May 4, 2011).
20. Adrian Kingsley-Hughes, So, Just How 'Open' Is Android As Far As Users Are Concerned?, ZDNET (May 3, 2011, 9:41 AM), http://www.zdnet.com/blog/ hardware/so-just-how-openis- android-as-far-as-users-are-concerned/12627
21. David M. Cutler et al., What Has Increased Medical-Care Spending Bought?, 88 AM. ECON. REV. 132, 132-36 (1998).
22. Genevieve P. Rosloff, "Some Rights Reserved": Finding the Space Between All Rights Reserved and the Public Domain, 33 COLUM. J.L. & ARTS 37, 79 (2009).
23. Jackie Hunter, Open-Source Pharmaceuticals?, PROJECT SYNDICATE (July 28, 2010), http:// www.project-syndicate.org/commentary/jhunter1/English.
24. Joseph A. DiMasi & Henry G. Grabowski, The Cost of Biopharmaceutical R&D: Is Biotech Different?, 28 MANAGERIAL&DECISION ECON. 469, 476 (2007).
25. Jolie Lee, New NIH Center Translates Research into Real-World Use, FEDERALNEWS RADIO.COM (Jan. 13, 2012, 8:48 AM), http://www.federalnewsradio.com/ 394/2705034/New-NIH-centertranslates- research-into-realworld-use;
26. Meredith Wadman, NIH Centre Faces Spell in Limbo, NATURE (Sept. 5, 2011), http://www.nature.com/news/2011/110905/full/477141a.html.
27. Develop Medicines, N.Y. TIMES, Jan. 22, 2011, http://www.nytimes.com/ 2011/01/23/health/policy/23drug.html?-r1&pagewanted
28. Amy Dockser Marcus, NIH Proposes New Center To Accelerate Drug Development, WALL ST. J. HEALTH BLOG (Dec. 8, 2010, 3:44 PM), http://blogs.wsj.com/health/2010/12/08/nih-proposes-newcenter- to-accelerate-drug-development/.